Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Cash (2019 - 2025)

Benitec Biopharma's Change in Cash history spans 7 years, with the latest figure at $25.3 million for Q1 2025.

  • For Q1 2025, Change in Cash rose 505.99% year-over-year to $25.3 million; the TTM value through Mar 2025 reached $89.5 million, up 1078.9%, while the annual FY2024 figure was $48.4 million, 3154.16% up from the prior year.
  • Change in Cash for Q1 2025 was $25.3 million at Benitec Biopharma, up from $10.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $36.8 million in Q2 2024 and bottomed at -$6.2 million in Q1 2024.
  • The 5-year median for Change in Cash is -$3.4 million (2021), against an average of $5.3 million.
  • The largest annual shift saw Change in Cash crashed 158.72% in 2022 before it surged 1002.4% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$3.4 million in 2021, then crashed by 76.46% to -$6.0 million in 2022, then increased by 8.46% to -$5.5 million in 2023, then skyrocketed by 290.2% to $10.4 million in 2024, then soared by 142.35% to $25.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Change in Cash are $25.3 million (Q1 2025), $10.4 million (Q4 2024), and $17.0 million (Q3 2024).